(Reuters) -OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Research consistently shows that social inequities and environment are key factors behind obesity disparities. If these new drugs live up to the hype, we may finally have a weight-loss tool that ...

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...

Wegovy contains the same main ingredient as Ozempic, semaglutide, and is FDA-approved for weight loss in people with obesity or who are overweight with at least one weight-related condition. It is ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

The exorbitant costs of drugs like Wegovy — especially compared to other countries — have prompted some insurers to tighten ...

The challenge of the obesity epidemic is widespread and one that even pediatricians face constantly,” a Connecticut doctor ...

New research shows that extreme weight loss and weight gain significantly increase the risk of death in obese individuals with cardiovascular disease.

State DHS officials say new weight-loss drugs are driving up costs for Pennsylvania’s Medicaid program, likely leading to ...